ArticleThe Journal of clinical investigation2026
Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
Hanchen Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.